Disease · MONDO_0002447
Comparisons in its trials21
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 21
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced a Serious Adverse Event (SAE) | 230 of 420 | 84 of 411 | 831 | NCT03884101 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Discontinued Study Intervention Due to an AE | 203 of 420 | 80 of 411 | 831 | NCT03884101 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced an Adverse Event (AE) | 418 of 420 | 405 of 411 | 831 | NCT03884101 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced an Immune-Related Adverse Event (irAE) | 316 of 420 | 56 of 411 | 831 | NCT03884101 | Trial comparisons |
| Arm I (Cisplatin, Radiation Therapy, Paclitaxel, Carboplatin) vs Arm II (Paclitaxel and Carboplatin): Number of Participants With Recurrence, Progression or Death | 132 of 370 | 139 of 366 | 736 | NCT00942357 | Trial comparisons |
| Arm I (Cisplatin, Radiation Therapy, Paclitaxel, Carboplatin) vs Arm II (Paclitaxel and Carboplatin): serious adverse events | 78 of 346 | 61 of 361 | 707 | NCT00942357 | Trial comparisons |
| Arm I (Pelvic Radiation Therapy) vs Arm II (Brachytherapy, Paclitaxel, Carboplatin): Number of Participants With Recurrence or Death Events at Primary Analysis | 44 of 301 | 43 of 300 | 601 | NCT00807768 | Trial comparisons |
| Arm I (Pelvic Radiation Therapy) vs Arm II (Brachytherapy, Paclitaxel, Carboplatin): Number of Participants With Death Events | 39 of 301 | 37 of 300 | 601 | NCT00807768 | Trial comparisons |
| Arm I (Pelvic Radiation Therapy) vs Arm II (Brachytherapy, Paclitaxel, Carboplatin): serious adverse events | 9 of 283 | 32 of 290 | 573 | NCT00807768 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: deaths from any cause | 34 of 74 | 25 of 56 | 130 | NCT04865289 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Experiencing an Immune-related AE (irAE) | 49 of 73 | 10 of 56 | 129 | NCT04865289 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Discontinuing From Study Treatment Due to an AE(s) | 32 of 73 | 8 of 56 | 129 | NCT04865289 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Experiencing a Serious Adverse Event (SAE) | 40 of 73 | 17 of 56 | 129 | NCT04865289 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Experiencing an Adverse Event (AE) | 72 of 73 | 56 of 56 | 129 | NCT04865289 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: serious adverse events | 40 of 73 | 17 of 56 | 129 | NCT04865289 | Trial comparisons |
| Durvalubmab vs Durvalubmab + Tremelimumab: Treatment Efficacy Determined by Measuring the Overall Response Rate | 5 of 40 | 4 of 40 | 80 | NCT03015129 | Trial comparisons |
| Durvalubmab vs Durvalubmab + Tremelimumab: deaths from any cause | 2 of 40 | 2 of 40 | 80 | NCT03015129 | Trial comparisons |
| Durvalubmab vs Durvalubmab + Tremelimumab: serious adverse events | 13 of 40 | 7 of 40 | 80 | NCT03015129 | Trial comparisons |
| Arm 1: Temsirolimus vs Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus: Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events Version 3.0 | 29 of 50 | 15 of 21 | 71 | NCT00729586 | Trial comparisons |
| Arm 1: Temsirolimus vs Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus: deaths from any cause | 33 of 50 | 16 of 21 | 71 | NCT00729586 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002447/comparisons